The (FDA) will approve this drug in less than 18 days!

< !DOCTYPE html>

Talon Therapeutics, Inc. (TLON)

Talon Therapeutics, Inc.
2207 Bridgepointe Parkway
Suite 250
San Mateo, CA 94404
United States - Map
Phone: 650-588-6404
Fax: 650-588-2787
Website: http://www.talontx.com

Talon Therapeutics, Inc., a biopharmaceutical company, develops and commercializes new and differentiated cancer therapies. The companys lead product candidate, Marqibo (vincristine sulfate liposomes injection), is a targeted Optisome encapsulated formulation product candidate for the treatment of adult acute lymphoblastic leukemia. Its product candidates also include Menadione topical lotion, a supportive care product candidate that has completed Phase I clinical trial for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors; Brakiva (topotecan liposome injection), a targeted Optisome encapsulated formulation product candidate, which is in Phase I dose-escalation clinical trial for the treatment of metastatic carcinoma of the ovary and small cell lung cancer sensitive disease; and Alocrest (vinorelbine liposome injection), an Optisomal encapsulated formulation product candidate that is in Phase I study for the treatment of advanced non-small cell lung cancer. The company was formerly known as Hana Biosciences, Inc. and changed its name to Talon Therapeutics, Inc. in December 2010. Talon Therapeutics, Inc. was founded in 2002 and is based in San Mateo, California.

Product Pipeline

We are very bullish on shares of Talon Therapeutics (TLON). We are placing a short term price target of $4.50 cents a share. Insiders are accumulating shares. The stock just broke another 52 week high today. They have a deep strong pipeline. The (FDA) will approve their lead drug in less than 18 days. The chart is very strong with heavy accumulation over the last 15 days.

Stock recommendations and comments presented on HotPennyStocksOnline.com are solely those of the analysts and experts quoted. They do not represent the opinions of HotPennyStocksOnline.com on whether to buy, sell or hold shares of a particular stock.

Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal or corporate ownership, may influence or factor into an expert stock analysis or opinion.

All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is no guarantee of future price
appreciation.

Anyone who stops learning is old, whether at twenty or eighty. Anyone who keeps learning stays young. The greatest thing in life is to keep your mind young.

Henry Ford

Kevin P. Ryan: President

Matthew Fisher: Vice President

Anthony Lero: Director of Marketing and Sales

Sample Headline

Hot Penny Stocks Online| Suite 2324| San Diego, Ca. 92111

To or change subscriber options visit:
/z/r/?jOysjAzMrLSsjCysnBzsnLRGtIysjIxMTEwM

Find more information about the above by searching here.

Comments Will Be Moderated